Highest-materiality recent filing
Senseonics shareholders approve doubling authorized shares to 140M
Increase authorized common stock from 70M to 140M shares, effective May 20, 2026.
Senseonics Q1 revenue up 87% to $11.7M; raises FY2026 guidance to $60-64M
Q1 revenue $11.7M (+87% YoY); US $9.3M, OUS $2.4M.
Senseonics amends loan agreement; up to $140M total, $20M expected to fund May 6
Amended loan agreement with Hercules Capital expands total commitment to $140M, with $80M committed and $60M uncommitted.
Senseonics prices $80M public offering, reports preliminary Q1 revenue $11.7M and net loss $31-33M
Offering: 8M shares + 8M pre-funded warrants at $5.00; net proceeds ~$74.7M ($86M if overallotment exercised). Underwriters have 30-day option for 2.4M additional shares.
On March 12, 2026, Senseonics entered into Local Purchase Agreements to acquire Ascensia's Eversense CGM assets in four European countries.
Senseonics Q4 revenue $14.3M (+72% YoY); guides FY26 revenue $58-62M
Q4 2025 revenue $14.3M (+72% YoY); US revenue $12.1M vs $6.2M in Q4 2024.
Senseonics Q4 2025 preliminary revenue $14.2M (+71% YoY); FY2025 $35.2M; guides FY2026 $58-62M
Preliminary Q4 2025 revenue $14.2M (+71% YoY); FY2025 revenue $35.2M (+57% YoY); cash $94.3M.
Senseonics closes $1.1M acquisition of U.S. Eversense assets from Ascensia
U.S. asset purchase closed Jan 1, 2026; cash consideration ~$1.1M for inventory, licenses, and leases.
Senseonics Q3 revenue $8.1M (+90% YoY); guides FY25 rev ~$35M; planning commercial transition
Q3 revenue $8.1M vs $4.3M YoY; U.S. revenue $6.4M (+167% YoY).
Senseonics Holdings announces 1-for-20 reverse stock split effective October 17, 2025
Reverse stock split ratio is 1-for-20, combining every 20 shares into 1.
Senseonics reports preliminary Q3 2025 revenue of ~$8.1M, up 91% YoY
Preliminary unaudited Q3 2025 revenue of approximately $8.1 million versus $4.2 million in Q3 2024.
Senseonics Q3 preliminary revenue $8.1M (+91% YoY); 1:20 reverse stock split effective Oct 17
Preliminary unaudited revenue $8.1M for Q3 2025, up 91% vs Q3 2024.
Senseonics shareholders approve reverse stock split of 1-for-10 to 1-for-20
Approved at special meeting on Sept 29, 2025; votes: 285.6M for, 178.2M against, 5.0M abstain.
Senseonics to take Eversense commercialization in-house, expands debt to $100M
MOU with Ascensia to transfer global Eversense commercialization to Senseonics by Jan 1, 2026; assets bought at book value.
Senseonics Q2 revenue $6.6M (+37% YoY); net loss narrows to $14.5M
Revenue $6.6M, up 37% YoY, driven by 79% U.S. new patient starts growth to $4.9M.
Senseonics shareholders elect directors, approve say-on-pay and KPMG ratification
Four director nominees elected: DeFalco, Hansen, Prince, Roeder; broker non-votes ~177M each.
Senseonics files technical amendment to prior 8-K; no new material information
Amendment to Form 8-K filed May 16, 2025, dated May 15, 2025.
Public offering of 100M shares priced at $0.50/share, with 15M-share overallotment option to underwriters.
Senseonics enters $25M private placement with Abbott; terminates ATM program
Up to $25M of common stock sold to Abbott at public offering price, closing within 2 days after public offering.
Senseonics Q1 revenue $6.3M, up 24% YoY; net loss narrows to $14.3M
Revenue $6.3M vs $5.0M YoY (+24%); U.S. $4.5M, OUS $1.8M.
Senseonics Q4 revenue $8.3M, net loss $15.5M; guides FY25 revenue $34-38M
Q4 revenue $8.3M (up from $8.0M YoY); net loss $15.5M ($0.02 loss per share).
Director Anthony Raab resigns from Senseonics board effective Jan. 17, 2025
Anthony Raab notified the Board of his resignation on January 17, 2025.
Preliminary Q4 revenue ~$8.3M; full year 2024 revenue ~$22.5M.
Senseonics updates corporate presentation at Stifel Healthcare Conference
Presentation highlights Eversense 365 CGM system FDA clearance and commercial launch.
Senseonics Q3 revenue $4.3M, gross loss $4.1M; Eversense 365 launch underway
Total revenue $4.3M, down ~30% YoY from $6.1M; U.S. revenue $2.4M vs $3.9M.
Senseonics prices $16M registered direct offering at $0.35/share with warrants
45,714,286 shares and matching warrants sold at combined $0.35 per unit.
Q2 revenue $4.9M (+18% YoY), net loss $20.3M; 365-day Eversense Q4 launch on track
Q2 2024 revenue $4.9M, up 18% vs $4.1M in Q2 2023; U.S. revenue $3.0M (+67%), OUS $1.9M.
Senseonics sees H1 2024 net rev $10M, +21% YoY; FY 2024 guidance $22-24M
Reaffirmed H1 2024 global net revenue $10M, 21% growth over H1 2023.
Senseonics stockholders approve increase in authorized common shares from 900M to 1.4B
Amendment to certificate of incorporation increases authorized common stock from 900M to 1.4B shares.
Senseonics Q1 revenue up 22% to $5.1M; net loss $18.9M vs income $1.3M
Revenue $5.1M (+22% YoY); U.S. $3.7M (+76%), OUS $1.4M (-30%).
On January 17, 2025, Anthony Raab, a director of Senseonics Holdings, Inc. (the “Company”) notified the Board of Directors of the Company (the “Board”) of his resignation from the Board effective as of January 17, 2025, in order to focus on his time commitments to his professional investment career, other board roles and family.
Max materiality 0.85 · Median 0.75 · Most common event earnings